Loading
What changed between revision 1 and revision 3, compared over the article's markdown source with its frontmatter — so a change to status, evidence or reversibility shows up as the edit it is.
Older · revision 1
Import· initial corpus import, not an edit
Initial import of content/personalized-mrna-cancer-vaccines.md — the filesystem corpus, unchanged. Not an edit.
18.9 kB
Revision 1
Revision 3
lines 8–14 → 8–147 unchanged lines not shown
categories: ["genetics", "longevity"]categories: ["genetics", "longevity"]tags: ["cancer", "mrna", "immunotherapy", "neoantigens", "melanoma", "oncology", "vaccines"]tags: ["cancer", "mrna", "immunotherapy", "neoantigens", "melanoma", "oncology", "vaccines"]summary: "A therapy in which one patient's tumour is sequenced, its mutation-derived antigens are ranked by algorithm, and a synthetic mRNA encoding them is manufactured for that person alone."summary: "A therapy in which one patient's tumour is sequenced, its mutation-derived antigens are ranked by algorithm, and a synthetic mRNA encoding them is manufactured for that person alone."updated: "2026-08-22"updated: "2026-10-29"humanEvidence: "A randomised phase 3 in 1,137 people with resected melanoma met its recurrence-free survival endpoint according to its sponsors, who released no hazard ratios; overall survival is unreported from it and only exploratory in the phase 2b behind it."humanEvidence: "A randomised phase 3 in 1,137 people with resected melanoma met its recurrence-free survival endpoint according to its sponsors, who released no hazard ratios; overall survival is unreported from it and only exploratory in the phase 2b behind it."access: "Available only inside company-run clinical trials; no individualized neoantigen therapy is approved by any regulator as of August 2026, and no price has been announced."access: "Available only inside company-run clinical trials; no individualized neoantigen therapy is approved by any regulator as of August 2026, and no price has been announced."reversibility: "partly-reversible"reversibility: "partly-reversible"lines 45–50 → 45–5430 unchanged lines not shown
A neoantigen is a protein fragment that exists only because a tumour mutated. It is absent from every healthy cell, which makes it a target the immune system can attack without attacking the patient. The difficulty is that neoantigens are almost entirely private to one tumour, so there is nothing to stock on a shelf.A neoantigen is a protein fragment that exists only because a tumour mutated. It is absent from every healthy cell, which makes it a target the immune system can attack without attacking the patient. The difficulty is that neoantigens are almost entirely private to one tumour, so there is nothing to stock on a shelf. ```figure{"key": "mrna-vaccine-mechanism", "caption": "The shared platform: lipid-nanoparticle delivery and translation in the recipient's cells. The per-patient step, choosing which 34 mutations the mRNA encodes, happens before this diagram begins."}``` The workflow answers that by manufacturing per patient. A biopsy and a blood sample are sequenced and compared, separating the tumour's mutations from the person's inherited variation. An algorithm then scores those mutations for the chance that a fragment carrying them will be displayed on the cell surface by that patient's own major histocompatibility complex molecules and recognised by a T cell. Moderna's product, intismeran autogene, encodes up to 34 of the top-ranked mutations in a single synthetic mRNA, made as a single-patient batch at the company's Massachusetts facilities and shipped to the trial site for intramuscular injection.[^moderna2026] The antigens are translated inside the recipient's cells rather than injected as peptides, so they enter the normal antigen-processing pathway.The workflow answers that by manufacturing per patient. A biopsy and a blood sample are sequenced and compared, separating the tumour's mutations from the person's inherited variation. An algorithm then scores those mutations for the chance that a fragment carrying them will be displayed on the cell surface by that patient's own major histocompatibility complex molecules and recognised by a T cell. Moderna's product, intismeran autogene, encodes up to 34 of the top-ranked mutations in a single synthetic mRNA, made as a single-patient batch at the company's Massachusetts facilities and shipped to the trial site for intramuscular injection.[^moderna2026] The antigens are translated inside the recipient's cells rather than injected as peptides, so they enter the normal antigen-processing pathway. Every advanced programme pairs the mRNA with a checkpoint inhibitor: priming new T cells accomplishes little if the tumour microenvironment then switches them off, so the vaccine supplies specificity and the antibody removes the brake. The trials measure a combination.Every advanced programme pairs the mRNA with a checkpoint inhibitor: priming new T cells accomplishes little if the tumour microenvironment then switches them off, so the vaccine supplies specificity and the antibody removes the brake. The trials measure a combination.lines 56–64 → 60–685 unchanged lines not shown
```timeline```timeline[[ { "year": "2010", "title": "First therapeutic cancer vaccine approved", "text": "The FDA approves sipuleucel-T for metastatic castration-resistant prostate cancer. Its pivotal trial extended median survival by roughly four months and did not delay disease progression at all." }, { "year": "2010", "title": "First therapeutic cancer vaccine approved", "text": "The FDA approves sipuleucel-T for metastatic castration-resistant prostate cancer. Its pivotal trial extended median survival by roughly four months and did not delay disease progression at all." }, { "year": "2013–2016", "title": "MAGE-A3 fails twice", "text": "GlaxoSmithKline's shared-antigen immunotherapeutic misses its endpoints in a phase 3 melanoma trial and then in the largest adjuvant lung cancer trial ever run. Both are abandoned." }, { "year": "2013-2016", "title": "MAGE-A3 fails twice", "text": "GlaxoSmithKline's shared-antigen immunotherapeutic misses its endpoints in a phase 3 melanoma trial and then in the largest adjuvant lung cancer trial ever run. Both are abandoned." }, { "year": "2017", "title": "Neoantigen vaccines reach patients", "text": "Two phase 1 studies published in Nature, one using synthetic peptides and one using RNA, show that vaccines built from an individual's own tumour mutations induce neoantigen-specific T cells in people with melanoma." }, { "year": "2017", "title": "Neoantigen vaccines reach patients", "text": "Two phase 1 studies published in Nature, one using synthetic peptides and one using RNA, show that vaccines built from an individual's own tumour mutations induce neoantigen-specific T cells in people with melanoma." }, { "year": "2019", "title": "KEYNOTE-942 opens", "text": "Moderna and Merck begin a randomised phase 2b of mRNA-4157 plus pembrolizumab against pembrolizumab alone in resected stage IIIB–IV melanoma." }, { "year": "2019", "title": "KEYNOTE-942 opens", "text": "Moderna and Merck begin a randomised phase 2b of mRNA-4157 plus pembrolizumab against pembrolizumab alone in resected stage IIIB-IV melanoma." }, { "year": "2023", "title": "Breakthrough therapy designation", "text": "In February the FDA grants the combination breakthrough therapy designation for adjuvant high-risk melanoma, on phase 2b data showing a 44% reduction in the risk of recurrence or death." }, { "year": "2023", "title": "Breakthrough therapy designation", "text": "In February the FDA grants the combination breakthrough therapy designation for adjuvant high-risk melanoma, on phase 2b data showing a 44% reduction in the risk of recurrence or death." }, { "year": "2023", "title": "Pancreatic cancer signal", "text": "A phase 1 study of BioNTech's autogene cevumeran in 16 patients with resected pancreatic cancer reports vaccine-expanded T cells in half of them, and longer recurrence-free survival in those who responded." }, { "year": "2023", "title": "Pancreatic cancer signal", "text": "A phase 1 study of BioNTech's autogene cevumeran in 16 patients with resected pancreatic cancer reports vaccine-expanded T cells in half of them, and longer recurrence-free survival in those who responded." }, { "year": "2024", "title": "Phase 2b published", "text": "Weber and colleagues report KEYNOTE-942 in The Lancet: 18-month recurrence-free survival of 79% with the combination against 62% with pembrolizumab alone, in 157 patients." }, { "year": "2024", "title": "Phase 2b published", "text": "Weber and colleagues report KEYNOTE-942 in The Lancet: 18-month recurrence-free survival of 79% with the combination against 62% with pembrolizumab alone, in 157 patients." },lines 69–75 → 73–794 unchanged lines not shown
## The melanoma result## The melanoma result INTerpath-001 enrolled 1,137 people whose stage IIB–IV cutaneous melanoma had been completely resected and who had received no prior systemic therapy. They were randomised two to one — double-blind, with placebo injections in the control arm — to intismeran autogene at 1 mg every three weeks for up to nine doses plus pembrolizumab, or to pembrolizumab alone, for about a year. Merck and Moderna reported on 19 August 2026 that an independent data monitoring committee found statistically significant and clinically meaningful improvements in recurrence-free survival and in distant metastasis-free survival, with no new safety signals.[^moderna2026] Moderna's shares more than doubled in early trading.[^fortune2026] That is the whole of the disclosed result: no hazard ratio, event count or survival curve.INTerpath-001 enrolled 1,137 people whose stage IIB-IV cutaneous melanoma had been completely resected and who had received no prior systemic therapy. They were randomised two to one, double-blind and with placebo injections in the control arm, to intismeran autogene at 1 mg every three weeks for up to nine doses plus pembrolizumab, or to pembrolizumab alone, for about a year. Merck and Moderna reported on 19 August 2026 that an independent data monitoring committee found statistically significant and clinically meaningful improvements in recurrence-free survival and in distant metastasis-free survival, with no new safety signals.[^moderna2026] Moderna's shares more than doubled in early trading.[^fortune2026] That is the whole of the disclosed result: no hazard ratio, event count or survival curve. The published record behind it is the 157-patient phase 2b, KEYNOTE-942, which reported 18-month recurrence-free survival of 79% with the combination against 62% with pembrolizumab alone.[^weber2024] At a median follow-up of 60.3 months the companies reported a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death. Fatigue, injection-site pain and chills were the common adverse events attributed to the therapy; immune-related events occurred in 45.2% of combination patients and 44% of those on pembrolizumab alone, so the mRNA did not appear to compound the checkpoint inhibitor's toxicity.[^asco2026]The published record behind it is the 157-patient phase 2b, KEYNOTE-942, which reported 18-month recurrence-free survival of 79% with the combination against 62% with pembrolizumab alone.[^weber2024] At a median follow-up of 60.3 months the companies reported a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death. Fatigue, injection-site pain and chills were the common adverse events attributed to the therapy; immune-related events occurred in 45.2% of combination patients and 44% of those on pembrolizumab alone, so the mRNA did not appear to compound the checkpoint inhibitor's toxicity.[^asco2026] lines 92–107 → 96–11116 unchanged lines not shown
Moderna and Merck listed nine phase 2 and phase 3 trials of intismeran autogene as of mid-2026, across melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma. None had reported.[^asco2026]Moderna and Merck listed nine phase 2 and phase 3 trials of intismeran autogene as of mid-2026, across melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma. None had reported.[^asco2026] The competing programme is BioNTech and Genentech's autogene cevumeran, an RNA-lipoplex therapy encoding up to 20 neoantigens per patient and given intravenously. Its phase 1 in resected pancreatic cancer expanded neoantigen-specific T cells in eight of sixteen patients, and those eight went longer without recurrence — a comparison of responders against non-responders inside one arm, not against a control.[^rojas2023] In first-line advanced melanoma the same therapy did not significantly improve progression-free survival against pembrolizumab alone, at a hazard ratio of 0.78 and a p value of 0.31, despite inducing neoantigen-specific T cells in about five of every six patients tested.[^imcode2025] That is the sharpest available reminder that an immune response is not an outcome.The competing programme is BioNTech and Genentech's autogene cevumeran, an RNA-lipoplex therapy encoding up to 20 neoantigens per patient and given intravenously. Its phase 1 in resected pancreatic cancer expanded neoantigen-specific T cells in eight of sixteen patients, and those eight went longer without recurrence, a comparison of responders against non-responders inside one arm rather than against a control.[^rojas2023] In first-line advanced melanoma the same therapy did not significantly improve progression-free survival against pembrolizumab alone, at a hazard ratio of 0.78 and a p value of 0.31, despite inducing neoantigen-specific T cells in about five of every six patients tested.[^imcode2025] That is the sharpest available reminder that an immune response is not an outcome. > [!debate] Does melanoma generalise?> [!debate] Does melanoma generalise?> Melanoma carries one of the highest mutation burdens of any common cancer — more candidate neoantigens per tumour — and already responds to checkpoint blockade better than most. Proponents argue the mechanism is antigen-agnostic and should transfer wherever there are enough mutations to choose from. Sceptics answer that it is being tested first where the immune system has the most to work with, and that the tumours responsible for most [[cancer|cancer deaths]] are the low-mutation ones where it has the least. The two positions agree about melanoma and disagree about lung and kidney cancer, which is why those readouts matter more than the one just delivered.> Melanoma carries one of the highest mutation burdens of any common cancer, meaning more candidate neoantigens per tumour, and already responds to checkpoint blockade better than most. Proponents argue the mechanism is antigen-agnostic and should transfer wherever there are enough mutations to choose from. Sceptics answer that it is being tested first where the immune system has the most to work with, and that the tumours responsible for most [[cancer|cancer deaths]] are the low-mutation ones where it has the least. The two positions agree about melanoma and disagree about lung and kidney cancer, which is why those readouts matter more than the one just delivered. ## Outlook## Outlook The result changes what is claimable about mRNA as a therapeutic platform more than what is known about cancer, and it rests on an interim analysis whose numbers nobody outside the sponsors and the monitoring committee has seen. Judging it needs the full dataset, an overall-survival readout, and the trials in tumours with fewer mutations.The result changes what is claimable about mRNA as a therapeutic platform more than what is known about cancer, and it rests on an interim analysis whose numbers nobody outside the sponsors and the monitoring committee has seen. Judging it needs the full dataset, an overall-survival readout, and the trials in tumours with fewer mutations. For the arguments this wiki tracks, the significance is narrower than the coverage suggests. An adjuvant therapy that delays recurrence in resected melanoma addresses one disease in one setting, the pattern the [[geroscience-hypothesis|geroscience]] argument treats as insufficient: eliminating a single cause of death shifts population life expectancy far less than the effort implies, because the same people remain at risk of everything else. The more general contribution may be methodological — a therapy specified by a patient's own sequence data and built in weeks is the production logic that [[organoids|patient-derived models]] and [[human-digital-twins|individualised simulation]] assume and have not delivered. Whether it survives contact with an ageing immune system is untested: the trials enrol patients fit enough for surgery and checkpoint blockade, and [[immunosenescence|the narrowing of the T-cell repertoire with age]] is exactly the constraint a therapy that depends on priming new clones would be expected to hit. Nothing about the current [[technology-readiness-level|readiness]] of the approach supports treating it as a general answer to [[compression-of-morbidity|late-life cancer mortality]].For the arguments this wiki tracks, the significance is narrower than the coverage suggests. An adjuvant therapy that delays recurrence in resected melanoma addresses one disease in one setting, the pattern the [[geroscience-hypothesis|geroscience]] argument treats as insufficient: eliminating a single cause of death shifts population life expectancy far less than the effort implies, because the same people remain at risk of everything else. The more general contribution may be methodological: a therapy specified by a patient's own sequence data and built in weeks is the production logic that [[organoids|patient-derived models]] and [[human-digital-twins|individualised simulation]] assume and have not delivered. Whether it survives contact with an ageing immune system is untested: the trials enrol patients fit enough for surgery and checkpoint blockade, and [[immunosenescence|the narrowing of the T-cell repertoire with age]] is exactly the constraint a therapy that depends on priming new clones would be expected to hit. Nothing about the current [[technology-readiness-level|readiness]] of the approach supports treating it as a general answer to [[compression-of-morbidity|late-life cancer mortality]]. ## See also## See also removed, struck through added, underlinedLine numbers count the serialised markdown of each revision, frontmatter included.
122 lines are the same in both revisions, and 84 of them are not shown. Neither revision here is necessarily the current article — read Personalized mRNA cancer vaccines for the text this wiki stands behind today.